TipRanks
pc:eradi

Eradivir Inc

Eradivir Inc. is a privately held, clinical-stage biotechnology company dedicated to leveraging the immune system to target and treat viral infections and other diseases. Utilizing its proprietary BAiT (Bispecific Antigenic immuno-Therapy) platform, Eradivir combines the simplicity of small molecule therapies with the efficacy of antibody therapies to enable rapid and selective destruction of diseased cells. The company's lead antiviral therapeutic, EV25, is in Phase 2 trials for influenza, while EV148 is being developed for respiratory syncytial virus (RSV).

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―
Estimated Valuation―
Total Amount Raised$10M
Total Amount Raised$10M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$10M
Latest Funding Amount$10M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 08, 2025
Investment
$10.00M
―

Similar Companies

A snapshot of private companies similar to Eradivir Inc, helping you discover and navigate related company profiles.

Related News and Analysis